Briovarx Infusion Services 308 LLC

Briovarx Infusion Services 308 LLC

Briovarx Infusion Services 308 LLC

Date Founded



460 South Benson Lane,Suite 11-12,Chandler, AZ 85224

Type of Company



Hospitals & Patient Services

Company Description

Briovarx Infusion Services 308 LLC sells home infusion therapy medical products. It also provides home infusion therapy services. The company was founded in 2005 and is headquartered in Chandler, AZ.

Executives & Employees

Founder & President

Chief Financial Officer

Vice President-Business Development

Paths to Briovarx Infusion Services 308 LLC
Potential Connections via
Relationship Science
Briovarx Infusion Services 308 LLC
Recent Transactions
Details Hidden

Briovarx Infusion Services, Inc., BriovaRx Infusion Services LLC, Harvest Partners LP purchase Briovarx Infusion Services 308 LLC from Shore Capital Partners LLC

Details Hidden

Raymond James Morgan Keegan's private equity investment arm is located in Memphis, Tennessee. The firm is a subsidiary of Raymond James Financial, Inc.

Details Hidden

Shore Capital Partners focuses on investments in lower middle-market companies in the healthcare sector. For platform investments, the firm targets companies with $5 million to $50 million and EBITDA of $1 million to $5 million. For add-on investments, companies should have at least $1 million in revenues. There is no minimum EBITDA requirement. Shore Capital Partners participates in: family succession transactions, MBOs, LBOs, recapitalizations, industry consolidations, growth investments and corporate divestitures.

Details Hidden

Tenth Street invests in small- to middle-market companies in the form of mezzanine debt. They provide capital for expansion acquisitions (including MBOs) and recapitalizations. Tenth Street manages the Tenth Street Fund II, LP which focuses on several industry sectors including commercial services, distribution and manufacturing. The Fund seeks companies with sustainable cash flow and revenues from $5 million to $50 million. Investments range from $1 million to $3 million, though they may participate in larger deals. Their investment structure may include subordinated debt with warrants and maturity within 3 to 5 years or preferred stock with current dividends

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Briovarx Infusion Services 308 LLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Briovarx Infusion Services 308 LLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Briovarx Infusion Services 308 LLC.